What is the consequence of decreased renal production of vitamin D on the body?

A. High-sensitivity C-reactive protein does not possess a direct enzymatic role in the lipolysis or breakdown of triglycerides. Adipose tissue metabolism is primarily regulated by hormones like insulin and catecholamines rather than inflammatory markers. While elevated CRP often correlates with metabolic syndrome, it does not function as a lipase in systemic circulation.

B. Increased levels of systemic inflammation, marked by high hs-CRP, are typically associated with decreased levels of high-density lipoprotein cholesterol. Inflammation can impair the reverse cholesterol transport system, leading to lower HDL-C levels and increased cardiovascular risk. This marker does not enhance the synthesis of protective lipoproteins but rather signals vascular stress.

C. Low-density lipoprotein production in the liver is governed by HMG-CoA reductase activity and intracellular cholesterol requirements, not by CRP levels. Although dyslipidemia and inflammation often coexist, hs-CRP is an acute-phase reactant rather than a direct metabolic stimulant for hepatic lipid synthesis. It serves as a biomarker for risk rather than a biosynthetic catalyst.

D. Elevated hs-CRP is a critical biomarker of low-grade systemic inflammation and vascular wall stress, which are essential drivers of atherogenesis. It contributes to the destabilization of atherosclerotic plaques and promotes the recruitment of monocytes into the arterial intima. Its presence indicates a heightened risk for coronary events independent of traditional lipid profiles.

A. The formation of prostatic cysts is an anatomical abnormality that can occur within the gland, but it is not the defining mechanism of BPH. BPH is specifically characterized by cellular hyperplasia rather than the development of fluid-filled sacs. Cysts may cause similar obstructive symptoms, but they represent a different pathological entity than benign glandular enlargement.

B. Increased production of androgens is not the cause of BPH; rather, the condition is driven by the intraprostatic conversion of testosterone to dihydrotestosterone (DHT) via 5-alpha reductase. While androgens are necessary for the development of BPH, systemic levels do not necessarily increase. The pathology stems from the sensitivity of prostatic tissue to DHT over time.

C. Inflammation and infection of the prostate gland are defined as prostatitis, which can cause acute or chronic pelvic pain and urinary symptoms. While BPH and prostatitis can coexist, the primary mechanism of BPH is non-inflammatory cellular growth. Chronic infection may exacerbate urinary symptoms, but it does not drive the benign proliferative changes of the transition zone.

D. Progressive enlargement of the prostate gland is the fundamental pathophysiological mechanism of BPH, resulting from the hyperplasia of epithelial and stromal cells. This growth primarily occurs in the transition zone, which surrounds the proximal urethra. As the gland expands, it causes mechanical compression of the urethral lumen, leading to the clinical manifestations of lower urinary tract obstruction.